|
Roche Group posts strong sales growth in the first quarter
|
11 April 2013 |
|
Roche launches new process for accessing clinical trial data
|
26 February 2013 |
|
FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer
|
24 February 2013 |
|
Roche delivers strong 2012 results
|
31 January 2013 |
|
Roche reports positive studies of MabThera given by subcutaneous injection
|
10 December 2012 |
|
Roche and the Innovative Medicines Initiative join forces to promote use of Nobel Prize-winning stem cell technology
|
06 December 2012 |
|
Results from the positive phase III AVAglio study
|
18 November 2012 |
|
Roche Group posts strong sales growth in the third quarter
|
16 October 2012 |
|
Roche leads healthcare sector in key sustainability index for fourth consecutive year
|
13 September 2012 |
|
Roche committed to innovation and growth
|
06 September 2012 |
|
Roche and Lucerne Festival renew partnership and launch new project for young composers
|
23 August 2012 |
|
FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
|
20 August 2012 |
|
The Phase III AVAglio study met its co-primary endpoint
|
13 August 2012 |
|
Roche reports second positive study of RoACTEMRA
|
29 July 2012 |
|
Roche to streamline research and development activities
|
26 June 2012 |
|
People with HER2-positive metastatic breast cancer lived longer with Roche's Perjeta
|
24 June 2012 |
|
Roche employees in 52 countries walk to raise funds to support vulnerable children worldwide
|
15 June 2012 |
|
FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer
|
13 June 2012 |
|
Trastuzumab emtansine (T-DM1) reduced the risk of cancer worsening or death
|
03 June 2012 |
|
Roche will report new data on important progress for people with advanced cancers at ASCO 2012
|
20 May 2012 |